Latest News
Transgene expands myvac platform into non-small cell lung cancer with TG4070
22 June 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Monday that it has initiated a randomised Phase 1 trial of TG4070, an individualised neoantigen therapeutic vaccine, in combination with nivolumab for the adjuvant trea...
BioArctic and Eli Lilly enter BrainTransporter collaboration with up to USD800m in milestone payments
22 June 2026 - Swedish research-based biopharmaceutical company BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) reported on Monday that it has entered into a research and collaboration agreement with US pharmaceutical firm Eli Lilly and Company to dev...
Fusion Antibodies secures Canadian patent allowance for antibody library technology
22 June 2026 - Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) declared on Monday that it has received a notice of allowance from the Canadian Intellectual Property Office for patent application no. 3,115,150 covering tw...
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB
22 June 2026 - Replicate Bioscience, a clinical-stage company developing novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, announced on Friday that it has been awarded a...
Sanofi's Sarclisa SC formulation gains Japanese approval to treat multiple myeloma
22 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combin...